2022
Catheter ablation improves cardiovascular outcomes in patients with atrial fibrillation and heart failure: a meta-analysis of randomized controlled trials
Simader FA, Howard JP, Ahmad Y, Saleh K, Naraen A, Samways JW, Mohal J, Reddy RK, Kaza N, Keene D, Shun-Shin MJ, Francis DP, Whinnett ZI, Arnold AD. Catheter ablation improves cardiovascular outcomes in patients with atrial fibrillation and heart failure: a meta-analysis of randomized controlled trials. EP Europace 2022, 25: 341-350. PMID: 36305545, PMCID: PMC9934993, DOI: 10.1093/europace/euac173.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Arrhythmia AgentsAtrial FibrillationCatheter AblationHeart FailureHumansRandomized Controlled Trials as TopicTreatment OutcomeConceptsHeart failure hospitalizationCatheter ablationHeart failureMedical therapyFailure hospitalizationAtrial fibrillationCardiovascular outcomesPrimary analysisPre-specified primary endpointAtrial fibrillation catheter ablationCause mortalityPrimary endpointSecondary endpointsLower riskPatientsTherapyHospitalizationFibrillationTrialsMortalityLow heterogeneityAblationEndpointOutcomesFailure
2013
Is bleeding a necessary evil? The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation
Myat A, Ahmad Y, Haldar S, Tantry US, Redwood SR, Gurbel PA, Lip GY. Is bleeding a necessary evil? The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation. Expert Review Of Cardiovascular Therapy 2013, 11: 1029-1049. PMID: 23984927, DOI: 10.1586/14779072.2013.815423.Peer-Reviewed Original ResearchConceptsStroke preventionAntithrombotic therapyAntithrombotic agentsNovel oral anticoagulation agentsAtrial fibrillation guidelinesOral anticoagulation agentsDrug-drug interactionsDirect antidoteAF patientsAnticoagulation monitoringAnticoagulation agentsAtrial fibrillationAbsolute riskAntithrombotic pharmacotherapyRelative riskLower riskStrong recommendationsPatientsThromboembolismPreventionRiskTherapyInherent risksAuthors' knowledgeAgentsRecent Developments in Understanding Epidemiology and Risk Determinants of Atrial Fibrillation as a Cause of Stroke
Ahmad Y, Lip GY, Lane DA. Recent Developments in Understanding Epidemiology and Risk Determinants of Atrial Fibrillation as a Cause of Stroke. Canadian Journal Of Cardiology 2013, 29: s4-s13. PMID: 23790597, DOI: 10.1016/j.cjca.2013.03.009.Peer-Reviewed Original ResearchConceptsDevelopment of AFAtrial fibrillationRisk factorsStroke riskAF patientsOccurrence of AFEffective oral anticoagulationAcute cardiac conditionsCause of strokeLow-risk patientsNovel risk factorsNovel therapeutic targetPublic health consequencesFormal anticoagulationOral anticoagulationRisk patientsPatient cohortCardiac conditionsEpidemic proportionsTherapeutic targetClinical practicePatientsAnticoagulationHealth consequencesRisk determinantsWarfarin for stroke prevention in atrial fibrillation: time to switch?
Ahmad Y, Lip G. Warfarin for stroke prevention in atrial fibrillation: time to switch? International Journal Of Clinical Practice 2013, 67: 603-605. PMID: 23758442, DOI: 10.1111/ijcp.12157.Peer-Reviewed Original ResearchPreventing Stroke and Systemic Embolism in Renal Patients with Atrial Fibrillation: Focus on Anticoagulation
Ahmad Y, Lip GY. Preventing Stroke and Systemic Embolism in Renal Patients with Atrial Fibrillation: Focus on Anticoagulation. Contributions To Nephrology 2013, 179: 81-91. PMID: 23652451, DOI: 10.1159/000346726.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnticoagulantsAtrial FibrillationBenzimidazolesBeta-AlanineClinical Trials as TopicComorbidityDabigatranDisease ManagementEmbolismFemaleFibrinolytic AgentsHemorrhageHumansHypertensionIntracranial EmbolismMaleMorpholinesPatient SelectionPyrazolesPyridonesRenal Insufficiency, ChronicRiskRisk FactorsRivaroxabanSeverity of Illness IndexStrokeThiophenesThrombophiliaWarfarinConceptsSevere renal impairmentAtrial fibrillationRisk factorsGeneral populationRenal impairmentRenal diseaseRenal patientsAbsence of AFLarge randomised control trialBenefits of warfarinNew oral anticoagulantsChronic kidney diseaseCohort of patientsRisk of strokeRandomised control trialEctopic vascular calcificationMajority of trialsUnique management challengesAF independentSystemic embolismOral anticoagulantsRenal insufficiencyStroke preventionThromboembolic riskStroke riskGone Fishing (for Silent Atrial Fibrillation)
Ahmad Y, Kirchhof P. Gone Fishing (for Silent Atrial Fibrillation). Circulation 2013, 127: 870-872. PMID: 23439445, DOI: 10.1161/circulationaha.112.000985.Peer-Reviewed Original Research
2012
New oral anticoagulants for stroke prevention in atrial fibrillation: impact of gender, heart failure, diabetes mellitus and paroxysmal atrial fibrillation
Ahmad Y, Lip GY, Apostolakis S. New oral anticoagulants for stroke prevention in atrial fibrillation: impact of gender, heart failure, diabetes mellitus and paroxysmal atrial fibrillation. Expert Review Of Cardiovascular Therapy 2012, 10: 1471-1480. PMID: 23253272, DOI: 10.1586/erc.12.148.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAnticoagulantsAtrial FibrillationDiabetes ComplicationsFemaleHeart FailureHumansMaleRisk FactorsSex FactorsStrokeWarfarinConceptsNew oral anticoagulantsParoxysmal atrial fibrillationOral anticoagulantsNonparoxysmal atrial fibrillationAtrial fibrillationHeart failureStroke preventionNew anticoagulantsContemporary phase III trialsAdditional prognostic benefitPhase III trialsPresence of diabetesNew drugsImpact of genderIII trialsPrognostic benefitDiabetes mellitusAnticoagulantsPatientsWarfarinEvent ratesCardiovascular medicineFibrillationMellitusDiabetesStroke Prevention in Atrial Fibrillation: Concepts and Controversies
Ahmad Y, Lip G. Stroke Prevention in Atrial Fibrillation: Concepts and Controversies. Current Cardiology Reviews 2012, 8: 290-301. PMID: 22920480, PMCID: PMC3492813, DOI: 10.2174/157340312803760820.Peer-Reviewed Original ResearchConceptsStroke risk factorsAtrial fibrillationOral anticoagulationStroke preventionRisk factorsPatient riskIndependent stroke risk factorNew oral anticoagulantsCommon cardiac rhythm disorderLow-risk patientsCardiac rhythm disordersAntiplatelet therapyAntithrombotic therapyOral anticoagulantsSevere strokePerioperative managementEffective therapyRhythm disordersEfficacious agentsGeneral populationNew agentsSimple scorePatientsAnticoagulationFibrillationDabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: NICE guidance
Ahmad Y, Lip GY. Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: NICE guidance. Heart 2012, 98: 1404. PMID: 22698856, DOI: 10.1136/heartjnl-2012-302101.Peer-Reviewed Original Research